_5CSZ.png) Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green).PDB:5CSZ. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Beta-amyloid (Aβ40/42) |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6496H10072N1740O2024S42 |
| Molar mass | 146276.71 g·mol−1 |
 N Y (what is this?) (verify) | |
Gantenerumab is amonoclonal antibody for the treatment ofAlzheimer's disease being developed byHoffmann-La Roche pharmaceuticals.[1][2]
Gantenerumab binds to and clears aggregatedbeta amyloid fibers.[3]
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.[4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease[5] but after five years of treatment, the drug did little to slow cognitive decline in patients.[6]
A study published in 2025 suggests that Gantenerumab appears to reduce the risk of Alzheimer's-related dementia in people with rare genetic mutations that cause the overproduction of amyloid in the brain. These people are normally destined to develop the disease in their 30s, 40s or 50s.[7]
Gantenerumab has been further developed intotrontinemab, which started a Phase III trial in 2025. Trontinemab consists of gantenerumab fused to Roche's proprietaryBrainshuttle module to help it cross theblood–brain barrier.[8]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byadding missing information. |
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |
